(Q45912924)

English

Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis--a prospective, non-randomized pilot study.

scientific article published on 11 October 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23057658

Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis--a prospective, non-randomized pilot study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23057658

multiple sclerosis

0 references

relapsing-remitting multiple sclerosis

0 references

Nicola De Stefano

8

object named as

N De Stefano

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

author name string

E Portaccio

1

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23057658

M L Stromillo

2

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23057658

B Goretti

3

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23057658

B Hakiki

4

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23057658

A Giorgio

5

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23057658

F Rossi

6

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23057658

A De Leucio

7

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23057658

M P Amato

9

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23057658

publication date

11 October 2012

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23057658

European Journal of Neurology

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23057658

20

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23057658

6

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23057658

986-990

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23057658

Cognitive changes in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03882.X

21 January 2018

Cognitive impairment predicts conversion to multiple sclerosis in clinically isolated syndromes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03882.X

21 January 2018

Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03882.X

21 January 2018

The contribution of MRI in assessing cognitive impairment in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03882.X

21 January 2018

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03882.X

21 January 2018

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03882.X

21 January 2018

The Rao's Brief Repeatable Battery and Stroop Test: normative values with age, education and gender corrections in an Italian population

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03882.X

21 January 2018

Association of MRI metrics and cognitive impairment in radiologically isolated syndromes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03882.X

21 January 2018

Accurate, robust, and automated longitudinal and cross-sectional brain change analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03882.X

21 January 2018

Evaluating and reducing the impact of white matter lesions on brain volume measurements.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03882.X

21 January 2018

Evidence of early cortical atrophy in MS: relevance to white matter changes and disability

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03882.X

21 January 2018

Reliability, practice effects, and change indices for Rao's Brief Repeatable Battery

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03882.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03882.X

21 January 2018

Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03882.X

21 January 2018

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03882.X

21 January 2018

Effect of interferon-beta-1b on cognitive functions in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03882.X

21 January 2018

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03882.X

21 January 2018

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03882.X

21 January 2018

The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03882.X

21 January 2018

Natalizumab may improve cognition and mood in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03882.X

21 January 2018

Identifiers

10.1111/J.1468-1331.2012.03882.X

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23057658

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23057658

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45912924&oldid=1235438113"